Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Continuous Glucose Monitoring Device Market Share, Size, Trends, Industry Analysis Report By End-Use; By Component Type; By Region; Segment Forecast, 2022 - 2029" report has been added to ResearchAndMarkets.com's offering.
The global continuous glucose monitoring device market size is expected to reach USD 14.78 billion by 2029 according to this new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
Increasing diabetes rates across the globe have led to increased cardiovascular diseases such as heart attack, strokes, kidney damage, and others, which is expected to boost the demand for these products over the forecast period. For instance, in 2019, as per the International Diabetes Federation (IDF), about 462.9 Billion people were affected by diabetes globally.
Technology advancement along with innovative features like ease of use, alarm, mealtime alerts, among others, is expected to benefit the industry growth. Furthermore, the outbreak of the COVID-19 pandemic has increased health-related concerns and awareness among individuals, which in turn is expected to increase the demand for the product over the forecast period.
North America is expected to hold the major share over the forecast period due to the presence of major industry players along with increasing technological advancement in these products. However, Asia Pacific is expected to grow at a significant rate due to increasing diabetic patients in countries such as China and India.
Some of the players operating in the global industry include Echo Therapeutics, Inc., A. Menarini Diagnostics, Abbott Laboratories, Dexcom, Inc., Bayer AG, Glycens, GlySens Incorporated, Insulet Corporation, F. Hoffmann-La Roche Ltd., STMicroelectronics, GE Healthcare, Johnson & Johnson, Medtronic plc, LifeScan, Medtrum Technologies, Inc., Micron Technology Inc., Microchip Technology Inc., Nemaura Medical, Inc., NXP Semiconductors, Novo Nordisk, Qualcomm, Senseonics Holdings, Inc., Roche Diagnostics, and Tandem Diabetes Care.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Continuous Glucose Monitoring Device Market Insights
4.1. Continuous Glucose Monitoring Device Market - Industry Snapshot
4.2. Continuous Glucose Monitoring Device Market Dynamics
4.2.1. Drivers and Opportunities
4.2.2. Restraints and Challenges
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Value Chain Analysis
4.6. Continuous Glucose Monitoring Device Industry trends
4.7. COVID-19 Impact Analysis
5. Global Continuous Glucose Monitoring Device Market, by Component Type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Continuous Glucose Monitoring Device, by Component Type, 2017 - 2029 (USD Billion)
5.3. Transmitters & Receivers
5.3.1. Global Continuous Glucose Monitoring Device Market, by Transmitters & Receivers, by Region, 2017 - 2029 (USD Billion)
5.4. Sensors
5.4.1. Global Continuous Glucose Monitoring Device Market, by Sensors, by Region, 2017 - 2029 (USD Billion)
5.5. Insulin Pumps
5.5.1. Global Continuous Glucose Monitoring Device Market, by Insulin Pumps, by Region, 2017 - 2029 (USD Billion)
6. Global Continuous Glucose Monitoring Device Market, by End-Use
6.1. Key Findings
6.2. Introduction
6.2.1. Global Continuous Glucose Monitoring Device Market, by End-Use, 2017 - 2029 (USD Billion)
6.3. Hospitals
6.3.1. Global Continuous Glucose Monitoring Device Market, by Hospitals, by Region, 2017 - 2029 (USD Billion)
6.4. Homecare Diagnostics
6.4.1. Global Continuous Glucose Monitoring Device Market, by Homecare Diagnostics, by Region, 2017 - 2029 (USD Billion)
6.5. Others
6.5.1. Global Continuous Glucose Monitoring Device Market, by Others, by Region, 2017 - 2029 (USD Billion)
7. Global Continuous Glucose Monitoring Device Market, by Geography
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. A. Menarini Diagnostics
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Echo Therapeutics, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Abbott Laboratories
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. Bayer AG
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. Dexcom, Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. F. Hoffmann-La Roche Ltd.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. GE Healthcare
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Glycens
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. GlySens Incorporated
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. Insulet Corporation
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development
9.11. Johnson & Johnson
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Recent Development
9.12. LifeScan
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Recent Development
9.13. Medtronic plc.
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Recent Development
9.14. Medtrum Technologies Inc.
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Recent Development
9.15. Microchip Technology Inc.
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Recent Development
9.16. Nemaura Medical, Inc.
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Recent Development
9.17. Novo Nordisk
9.17.1. Company Overview
9.17.2. Financial Performance
9.17.3. Product Benchmarking
9.17.4. Recent Development
9.18. NXP Semiconductors
9.18.1. Company Overview
9.18.2. Financial Performance
9.18.3. Product Benchmarking
9.18.4. Recent Development
9.19. Qualcomm
9.19.1. Company Overview
9.19.2. Financial Performance
9.19.3. Product Benchmarking
9.19.4. Recent Development
9.20. Roche Diagnostics
9.20.1. Company Overview
9.20.2. Financial Performance
9.20.3. Product Benchmarking
9.20.4. Recent Development
9.21. Senseonics Holdings, Inc.
9.21.1. Company Overview
9.21.2. Financial Performance
9.21.3. Product Benchmarking
9.21.4. Recent Development
9.22. STMicroelectronics
9.22.1. Company Overview
9.22.2. Financial Performance
9.22.3. Product Benchmarking
9.22.4. Recent Development
9.23. Tandem Diabetes Care
9.23.1. Company Overview
9.23.2. Financial Performance
9.23.3. Product Benchmarking
9.23.4. Recent Development
For more information about this report visit https://www.researchandmarkets.com/r/gk5bu
Attachment
